These findings suggest that ERCC1 expression is a double-edged sword in NSCLC, simultaneously being a significant and independent prognostic factor of survival in NSCLC and also being associated with increased resistance to platinum-based chemotherapy [9-14]. The gene discussed is ERCC1; the disease is non-small cell lung carcinoma.